The joint venture co-built by Evonik China Co., Ltd. and Shandong Vland Biotech Co., Ltd. was officially put into operation on March 14, 2024, in Qingdao, China. It aims to develop and expand gut health solutions products including probiotics for farm animals in China.

As part of Evonik's life science division Nutrition & Care, the Animal Nutrition business line is committed to providing biosolutions including probiotics for animal gut health for the feed industry. Cooperation with Vand is an important step in realizing this strategy, said Johann-Caspar Gammelin, head of the business segment. "Working closely with Vland over the past decade has laid the foundation for a deeper partnership."

Evonik's biotech platform focuses on integrating innovations in the fields of chemistry, biotech, pharmacology and data science to develop biosolutions, thereby creating new opportunities for its growth.

"Vland and Evonik have been expanding and deepening our cooperation areas in the past decade. The joint venture will make full use of and give full play to each other’s strengths and deliver efficient products and solutions in animal gut health for users both in China and abroad,” said Chen Gang, chairman and president of Vland Group.

The joint venture is headquartered in Vland Biotech Innovation Park in Qingdao, China, and Vland’s production facilities in Binzhou, Shandong Province, China., will be utilized.

"Benefiting from the strong innovation capabilities, applied technology expertise and excellent reputation of the two parent companies, we will deliver innovative products and solutions to the market, and create more value for our customers," said Wang Xu, general manager of Evonik Vland Biotech (Shandong) Co., Ltd.

As part of the agreement, Evonik will distribute the joint venture’s portfolio outside of the Greater China Region. The joint venture allows Evonik to expand its gut health solutions by adding broader formulation elements to its global product portfolio.